inhibitory glp 1 GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica GLP-1-based therapies for type 2

Like other chronic diseases, we need a range of treatment options to address the individual needs of people with obesity, such as their own specific response to treatment. When evaluating the treatment effect regardless of adherence, * * average weight loss with cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks

H.GuG.et al (2018)

American Journal of Physiology 2006291R367R375

Some Patient Populations Are at Higher Risk Other populations at higher risk for VTE include people with chronic illnesses, such as heart disease and inflammatory bowel disease, as well as those with high estrogen because of pregnancy, oral contraceptives, or hormone replacement therapy, notes Cleveland Clinic